On March 7, 2023 Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, reported that Oren Gilad, Ph.D., President and Chief Executive Officer, will present a corporate overview and host 1×1 meetings at the Oppenheimer 33rd Annual Healthcare Conference, being held online from March 14-16, 2023 (Press release, Aprea, MAR 7, 2023, View Source [SID1234628245]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oppenheimer 33rd Annual Healthcare Conference
Date: Tuesday, March 14, 2023
Time: 10:00 a.m. ET

A live webcast of the presentation will be available in the "Upcoming Events" section under the "News and Events" tab of the Company’s website (www.aprea.com). A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.